stockrow
Friday 6 November 2026
Export EVH’s income statement to Excel — free account
Evolent Health, Inc
EVH Healthcare Health Information Services
Evolent Health, Inc’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 26.6% from fiscal 2024.
- Revenue
- +51.3%
- EPS
- +12.5%
- Free cash flow
- +179.8%
- Total debt
- −8.09%
Quarter to September 2026, against a year earlier
4.60
0.06
+1.32%
Follow EVH
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.17 | 0.29 | 0.14 | 0.24 | |
P/FCF ratio |
10.77 | 25.06 | 182.90 | 96.07 | |
P/Operating CF |
14.96 | (65.50) | (259.29) | 9.36 | |
P/B ratio |
1.06 | 1.59 | 0.64 | 1.10 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.52 | 0.69 | 0.56 | 0.67 | |
EV/EBITDA |
12.11 | 14.39 | 9.81 | 10.56 | |
EV/Operating CF |
18.64 | 26.47 | 31.92 | 32.16 | |
EV/FCF |
32.99 | 59.07 | 761.74 | 262.75 | |
Quick Ratio |
1.22 | 1.19 | 1.26 | 1.27 | |
Current Ratio |
1.26 | 1.24 | 1.32 | 1.31 | |
Net Debt/EBITDA |
0.00 | 51.48 | 54.43 | 20.35 | |
Debt/Assets |
49.41% | 49.01% | 51.81% | 51.10% | |
Debt/Equity |
2.60 | 2.52 | 2.46 | 2.34 | |
Asset Turnover |
1.06 | 0.95 | 0.83 | 0.84 | |
Operating CF/Net income |
(1.12) | 0.33 | 0.04 | (0.11) | |
Capex/Depreciation |
0.00 | (0.27) | (0.25) | (0.02) | |
Interest Coverage |
(0.36) | (0.57) | (0.63) | (21.47) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
10.08% | 10.55% | 14.67% | 15.50% | |
Intangible Assets out of Total Assets |
0.63 | 0.63 | 0.67 | 0.67 | |
Share Based Compensation of Revenue |
2.04% | 2.33% | 2.15% | 0.51% | |
Graham Net Nets |
(2.46) | (1.60) | (3.84) | (2.14) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(130.09%) | (84.32%) | (208.77%) | (128.75%) | |
Free Cash Flow Yield |
9.29% | 3.99% | 0.55% | 1.04% | |
Revenue per Share |
6.42 | 5.80 | 4.43 | 4.10 | |
Operating CF per Share |
0.23 | (0.08) | (0.01) | 0.43 | |
Capex per Share |
(0.06) | (0.06) | (0.06) | (0.07) | |
Free Cash Flow per Share |
0.17 | (0.14) | (0.07) | 0.36 | |
Cash per Share |
1.37 | 1.23 | 1.48 | 1.56 | |
Shareholders Equity per Share |
3.30 | 3.41 | 3.54 | 3.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.30 | 3.41 | 3.54 | 3.64 | |
Free Cash Flow |
19.17 | (16.16) | (7.39) | 41.04 | |
Working Capital |
127.18 | 117.68 | 120.78 | 121.11 | |
Capital Expenditures |
(7.21) | (6.85) | (6.41) | (7.76) | |
Net Current Asset Value |
(972.19) | (978.16) | (980.44) | (977.67) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
414.67 | 403.94 | 372.33 | 362.27 | |
Average Payables |
55.01 | 54.14 | 60.41 | 77.90 | |
Average Assets |
2,207.81 | 2,216.71 | 2,266.15 | 2,221.82 | |
Average Common Equity |
607.54 | 639.61 | 665.96 | 708.23 |
Columns are period end dates · fundamentals updated 5 Nov 2026